Asieris' CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
PR Newswire —
SHANGHAI, March 3, 2026 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women's health, announced today that its core product APL-1702 (trade name: CEVIRA®, Hexaminolevulinate Hydrochloride...